The second coming of consumer genomics with 3 predictions for 2018
Several fundamentals have changed to accelerate growth in the genomics space, spurring our second look into the sector.
UBS: Immunotherapy one of the hottest investment targets
The rising levels of efficacy when using cancer immunotherapy - as well as the rising costs of patient treatments - are making this a lucrative field to Wall Street, a top executive at UBS says.
presented by
Redefining Payer Operations: Data-Driven Strategies for the Future of Healthcare
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.